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Abstract
Introduction—Despite estimates of a high prevalence of deep dyspareunia (DD) among women 
in the US, risk factors for this important area of sexual dysfunction have been largely 
understudied.
Aims—The purpose of this study was to examine the relationship between uterine fibroids and 
the prevalence of deep dyspareunia (DD).
Methods—We used data from the Uterine Fibroid Study (enrollment 1996–1999 in a U.S. 
metropolitan area). Participating women were ages 35–49 and were randomly selected from the 
membership rolls of a prepaid health plan. Women were asked to provide detailed health 
information including a symptom questionnaire with questions about DD, and to have a study 
ultrasound to screen for fibroids ≥ 0.5 cm diameter. The analysis included 827 women, after 
restriction to participants who were premenopausal with an intact uterus, sexually active, 
completed the symptom questionnaire, and had fibroid status adequately assessed. Logistic 
regression was conducted to estimate the adjusted prevalence odds ratio (aPOR) for the association 
of DD with presence of fibroids, after adjusting for age, ethnicity, education, depression, physical 
activity, parity, and pelvic pathology.
Main Outcome Measure—Our main outcome measures were the presence and severity of DD.
Results—The presence of fibroids was significantly associated with DD (aPOR= 1.7 95% CI 1.1, 
2.5). The aPOR was stronger for severe DD, DD that interfered with normal activity “some” or “a 
lot” (aPOR= 3.1 95% CI 1.2, 8.2). However, there was not a significant dose response relationship 
between fibroid burden (measured by uterine volume) and DD. Fundal fibroids were more strongly 
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associated with DD than other fibroids. Additional factors associated with significantly elevated 
odds of DD were parity, depression, younger age, and pelvic pathology.
Conclusion—Our results suggest that fibroids are associated with DD. The association may not 
be causal, but may reflect shared etiology and/or pathologic pathways.
Introduction
The causes and impact of deep dyspareunia, a form of sexual dysfunction has been largely 
understudied despite prevalence estimates ranging from 10%–40% [1,2,3]. The importance 
of this life-style issue has gained recent attention because of studies that have revealed high 
prevalence of sexual dysfunction among older menopausal women, but few data exist for 
premenopausal women [4]. Moreover, national attention and investigation of issues 
impacting relationship and marital quality have come to the forefront as the dissolution of 
marriage has remained high [5]. While deep dyspareunia is only one small aspect of sexual 
dysfunction, it is thought to precede and worsen other common sexual dysfunctions such as 
loss of desire, the most common sexual dysfunction seen in post-menopausal women [6].
Pelvic pathologic conditions such as endometriosis and interstitial cystitis are well known 
and accepted contributors to the development of chronic pelvic pain including dyspareunia; 
however the importance of fibroids has not been as clear [6]. Previously reported 
associations between fibroids and DD have been weak to moderate in magnitude [7,8,9], 
requiring larger samples to more precisely estimate an association. Most studies were small 
and only one used ultrasound to systematically detect fibroids [9]. The Uterine Fibroid Study 
offered the opportunity to look at the association between fibroids and deep dyspareunia 
using a large population-based resource of primarily premenopausal African American and 
Caucasian women. We hypothesized that fibroids are a significant contributor to the 
presence and severity of DD among women.
Aims
1. To examine the association between fibroids and deep dyspareunia.
2. To evaluate if fibroids contribute to dyspareunia severity (measured by DD 
interference with normal activity).
3. To examine the dose response relationship between fibroid burden (measured by 
size of uterus) and deep dyspareunia.
4. To describe the contribution of other a priori chosen covariates towards the 
presence of deep dyspareunia.
Methods
We used previously collected cross-sectional data from the Uterine Fibroid Study (UFS) to 
conduct this analysis. The UFS enrolled a sample of 35–49 year old women who were 
randomly selected from the membership rolls of a prepaid health plan located in Washington 
DC. The response rate was over 80% with a total of 1430 women participating in the initial 
enrollment during 1996–1999. The study has been described in detail [10]. Briefly, all 
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women were asked to complete a self-administered questionnaire about, medical history, 
dietary and occupational exposures, as well as symptoms related to fibroids. Premenopausal 
women were then screened with pelvic ultrasound to detect the presence of fibroids, 
regardless of prior clinical diagnosis. Women excluded from this analysis were: 1.) women 
who were naturally or surgically menopausal including either a hysterectomy and/or a 
bilateral oophorectomy (n=190), 2.) women who were not sexually active over the past year 
(n= 196), 3.) women who did not follow-up to complete the symptom questions which 
included assessment of dyspareunia (n= 163), and 4.) women who did not have fibroid status 
determined (n=55). This left a total of 827 women for this analysis (Figure 1). The Uterine 
Fibroid Study was approved by the National Institute of Environmental Health Sciences and 
George Washington University Human Subject Review Boards. Participants gave informed 
consent. This secondary data analysis was approved by the University of North Carolina at 
Chapel Hill IRB board.
Dyspareunia Assessment
Participants were asked to complete a self-administered questionnaire at enrollment, prior to 
ultrasound examination. Deep dyspareunia (DD) was assessed with the following questions:
Have you experienced pain deep inside during sexual intercourse more than once or twice in 
the past twelve months?
1. Yes
2. No
3. Not having sex
If yes, on average, how many days do you experience this symptom?
1. Less than 1 day per month
2. 1–4 days per month
3. More than 4 days a month
If yes, on days when you have this symptom, how much does it prevent you from carrying 
out your normal activities?
1. None or a little
2. Some
3. A lot
Women who answered yes were considered to have DD. Women who had DD that prevented 
normal activity “some” or “a lot” as contrast to “none” or “a little”, were classified as having 
severe DD. Similar questions were asked regarding pain around the vaginal opening during 
sexual intercourse. Pain at opening was not included as part of the main outcome measure, 
but was included in the descriptive analysis. Thus, we had two outcome variables 1.) one 
variable that measured the presence or absence of DD (yes/no), and 2.) one variable that 
measured DD severity (i.e., DDsevere =pain that prevents normal activity normal activity 
“some” or a “lot”).
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1. Deep Dyspareunia- (yes/no)
2. Severe Deep Dyspareunia- (DDsevere =pain that prevents normal activity normal 
activity “some” or a “lot”).
Fibroid Assessment
For participants who had undergone a recent clinic ultrasound examination at the 
participating clinic, we assigned fibroid status on the basis of that examination. Other 
participants were asked to undergo both a transvaginal and transabdominal study ultrasound 
to determine fibroid status. During the study ultrasound examination the two largest fibroids 
over 2.0 cm in diameter were evaluated for size, location, and position. The evaluated 
fibroids were measured in three planes (longitudinal, anterior-posterior, and transverse). The 
number of fibroids was not systematically tracked, so women with numerous fibroids did not 
have had all fibroids evaluated. All sonographers were certified by the American Registry of 
Diagnostic Medicine and were under the supervision of a radiologist with fellowship 
training in sonography. A total of 78% (n=631) had fibroid status determined by study 
ultrasound and 22% (n=175) had fibroids status determined by recent ultrasound exam. A 
total of 2.5% (n=21) women had fibroid status determined by self-report. We only used self-
report data for women who reported “yes” when asked if they had a clinical diagnosis of 
fibroids because fibroids were frequently found at ultrasound that had not been previously 
diagnosed [10].
We classified fibroid burden in two ways. First, we created a dichotomous yes/no variable. 
Second, we created a 4–level variable for fibroid burden as measured by uterine volume (no 
fibroids, fibroid/s present with uterine volume <150cm3, fibroid/s present with uterine 
volume ≥150cm3 but <300cm3, fibroid/s present with uterine volume ≥ 300cm3). Uterine 
volume was used as a measure of fibroid burden because only the two largest fibroids ≥ 2.0 
cm were measured. Therefore, we could not sum volumes across all fibroids.
Evaluated fibroids were also classified based on their location with respect to the uterine 
axis and the uterine layers. Fibroid location with respect to the uterine axis was defined as: 
1.) fundus – upper third of the uterus, 2.) corpus – the middle third of the uterus, or 3.) lower 
uterine segment/cervix – lower third of the uterus. Location was recorded for the two largest 
fibroids ≥ 2.0 cm in diameter. Evaluated fibroids were also classified with respect to the 
uterine layers. They could be: 1.) intramural- within the uterine wall, 2.) subserosal 
protruding outside the uterine wall, or 3.) submucosal- impinging on the uterine cavity.
Covariate Assessment
Potential confounders were chosen a priori on the basis of the literature. Some variables 
were assessed from the self-administered questionnaire (ethnicity, education, and history of 
depression, i.e., ever told by a doctor or a health care professional that she had a history of 
depression). Other variables were assessed through a structured interview (age, number of 
deliveries, and physical activity). Alcohol and body mass index (BMI) disease were also 
evaluated as possible confounders but were not included in the final model as they did not 
influence the association observed between fibroids and DD. Self-reported ethnicity was 
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categorized using disjoint indicator coding (African American, Caucasian, and other). We 
did not distinguish between the type of delivery (C-section or vaginal), however 
approximately 20% (n=163) of the study population had at least one C-section, and 7% 
(n=58) had 2 or more C-sections.
The pelvic pathology variable included women with a self-reported history of at least one of 
the following: endometriosis, uterine prolapse, or interstitial cystitis (which was inferred by 
symptom history). Of the 77 women who reported the presence of pelvic pathology, 58 
reported endometriosis as at least one of their diagnosis, 14 women reported having 
prolapse, and 8 women reported frequent painful urination more than 4 days per month over 
the past year (some women reported more than 1 of these). Non-occupational physical 
activity was categorized as vigorous, moderate, or mild (walking) and number of hours per 
week doing these activities was recorded. A summary variable based on estimated metabolic 
scores for the activities was created (low= lowest 33 percent of the distribution, medium= 
middle 33 percent, high= 67th–83rd percentile, and very high= above the 83rd percentile) 
[11]. Body mass index was calculated based on measured weight from the study clinic visit, 
and categorized as: 25, 25–29, 30–34, 35 and over. Alcohol use was assessed by interview 
and categorized by the number of drinks per week (0–0.5, 1–2, 3–6, 7 or more).
Statistical Analysis
Chi-squared statistics were used to assess descriptive differences in proportions of associated 
symptoms between women with DD and women without DD. Multivariate logistic 
regression analysis was used to assess the relationship between the presence of fibroids and 
deep dyspareunia. Multinomial logistic regression was used to assess the relationship 
between the presence of fibroids and severe DD (DD that prevented normal activity “some” 
or “a lot”). Covariates were modeled using the categorizations shown in Table 1, except age 
and number of deliveries which were both kept as continuous variables.
Prevalence odds ratios (PORs) and 95% confidence intervals (95% CI) were calculated. 
PORs were adjusted for age, ethnicity, education, number of previous deliveries, depression 
history, pre-existing diagnosis of pelvic pathology, and physical activity. To evaluate the 
association between the presence of fibroids and severe DD, we created a three tier outcome 
variable for DD (No DD, DDmild =pain that prevents normal activity “none” or “a little”, and 
DDsevere =pain that prevents normal activity “some” or “a lot”). To evaluate the dose 
response relationship between fibroid burden and DD, we calculated the POR for DD for 
each level of fibroid burden (as measured by uterine volume categories), and compared them 
to women with no fibroids as the reference group.
Exploratory analyses were conducted to see if our data are consistent with a prior report 
linking fundal fibroids to DD [9]. We evaluated having a fibroid in the fundal location as a 
predictor of DD, among women with fibroid location data (n= 513). Similar analysis was 
done to evaluate retroversion of the uterus as a predictor of DD. Our fundal location data are 
limited because we only evaluated a woman’s largest two fibroids ≥ 2.0 cm. Thus, our 
fibroid location analysis must be viewed as exploratory. A supplemental analysis was 
conducted to investigate how the association between fibroids and DD may be modified by 
pelvic pathology. We stratified the analysis by the presence or absence of pelvic pathology. 
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We conducted a likelihood ratio test comparing the model with only the main effect of 
fibroids to the one with the added interaction term for pelvic pathology and fibroids. The 
alpha level of 0.10 for this test was chosen a priori.
All analysis was performed using SAS version 9.3 (SAS Institute, Cary NC) and Microsoft 
Excel version 2010 was used to conduct a likelihood ratio test (LRT).
Results
Among women with fibroids, 22% (n= 113) reported the presence of deep dyspareunia over 
the past year, while only 15% (n=46) of women with no fibroids reported DD (unadjusted P-
Valuedifference = 0.02). Compared to those without dyspareunia, women with the condition 
tended to be younger, African American, to have less education, more deliveries, to have 
reported a history of depression, and were more likely to have been diagnosed in the past 
with other pelvic pathology (endometriosis, prolapse, and interstitial cystitis) (Table 1). 
Forty-six percent of those with DD reported that they also had this condition at age 30 
compared to 4% of those without a current report of DD. Women with DD also had more 
pelvic and abdominal pain symptoms compared to those without DD (Table 1). Women with 
more frequent DD had a higher prevalence of fibroids than women with less frequent DD 
(Table 2). For example 78% of the women who reported DD four or more days per month 
had fibroids, while 58% of those with DD less than one day a month had fibroids.
In the study sample, the POR between fibroids and DD (yes/no) after adjustment for age and 
ethnicity was 1.4 (95% CI 0.98, 2.18). Adjusting for age, ethnicity, number of deliveries, 
depression, physical activity, and education the association between fibroids and DD was 
slightly stronger aPOR= 1.7 (95% CI 1.09, 2.54) (Table 3). Of the 159 participants reporting 
yes to DD, 34 women reported severe DD (pain that prevents normal activity “some” or “a 
lot”). In multinomial regression analysis adjusting for the same variables used in the overall 
DD analysis (yes/no), the association between fibroids and severe DD was stronger 
aPORDDsevere= 3.1 (95% CI 1.20, 8.18).
When we examined the dose response relationship between fibroid burden (as measured by 
uterine volume), we did not observe a significant increase in the odds of DD with increasing 
uterine volume (Table 4). We also evaluated fibroid location with respect to uterine axis as a 
potential predictor of DD. One hundred and sixty-five women had at least one fundal fibroid, 
and 72 had only non-fundal fibroids. We observed fundal fibroids to be somewhat more 
strongly associated with DD compared to non-fundal fibroids (aPORfundal_fibroid = 2.9 95% 
CI 1.4, 5.9 vs. aPORnonfundal_fibroid = 1.6 95% CI 0.9, 2.9). However, confidence intervals 
overlapped between the two groups. In the supplemental analysis, we found that the 
presence of pelvic pathology did not appear to significantly modify the association between 
fibroids and DD. The association between fibroids and DD among women without pelvic 
pathology present was aPOR= 1.7, and the association between fibroids and DD among 
women with pelvic pathology present was aPOR= 1.5 (Pinteraction= 0.6).
Other factors associated with a significantly elevated odds of DD were parity, depression, 
younger age, and the presence of other pelvic pathology (Table 3). There was a 30% 
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increased odds of DD for each delivery. Women with a history of depression had a 2 fold 
increased odds of having DD compared to women without a history of depression. Older 
premenopausal women were slightly less likely to have DD as compared to younger 
premenopausal women. As expected women with pelvic pathology present had almost 3 
times the odds of having DD as compared to women without pelvic pathology present.
Discussion
We found that fibroids were significantly associated with DD aPOR = 1.7 (95% CI 1.09, 
2.54), and that the association was stronger for severe DD. Compared to women without 
fibroids, those with fibroids had a 3-fold odds of having severe DD (DD that prevented 
normal activity “some” or “a lot”). We did not observe a dose response relationship between 
fibroids and DD in that increasing uterine volume did not appear to increase the odds of DD. 
Consistent with previous findings [9], fundal fibroids tended to be more strongly associated 
with DD than non-fundal fibroids. Other factors that were associated with an increased odds 
of DD included increasing number of deliveries, a history of depression, the presence of 
pelvic pathologic condition (i.e., endometriosis, prolapse), and younger age.
The association between deep dyspareunia and fibroids has not been well studied and 
previous findings are mixed. While there are anecdotal and case reports of dyspareunia 
being caused by fibroids [11], few epidemiologic studies have examined this association 
[7,8,9]. A small hospital based case-control study that compared the prevalence and severity 
of DD between women undergoing surgery for other benign conditions to women with 
symptomatic fibroids, found no difference in the prevalence and severity of DD among the 
comparison groups [7]. Lippman et al. conducted a cross sectional analysis looking at the 
association between fibroids and pelvic pain including the presence of deep dyspareunia 
(population based sample from the Seveso Women’s Health Study conducted in 1976) [9]. 
They found that women with fibroids were more likely to report mild and severe 
dyspareunia (ORmild = 1.4, ORsevere 1.8). They measured DD severity by self-report of 
avoiding intercourse because of pain. Another hospital based case–control study that 
compared fibroid symptoms between women with sporadic fibroids (n=255) and women 
with familial fibroids (n=45), observed that women with familial fibroids had a higher 
prevalence of dyspareunia as compared to women with sporadic fibroids (43% versus 28% 
p-value= 0.01) [8]. They attributed the increase in pain symptoms to: 1.) an increased 
number of fibroids observed in the familial group as compared to the sporadic group and 2.) 
an increased expression of vasoactive substances such as VEGF-A found in heavier 
concentrations in fibroid tissue of familial fibroids as compared to sporadic fibroids (64% 
vs. 28%) [8]. Similar to our study, all the prior studies used cross-sectional data to evaluate 
the association. However, only one study used ultrasound screening to define fibroid status 
[9], and none of the prior studies adjusted for the number of deliveries which is likely to be a 
strong confounder in most populations.
Though we found that fibroids and DD were significantly associated, we did not find that the 
odds of DD increased with fibroid burden as measured by uterine volume. This is consistent 
with some [7,9], but not all, previous studies [8]. Several factors could have influenced this 
unexpected null finding. First, women with large symptomatic fibroids may be more likely 
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to have had a prior hysterectomy, and women with surgical menopause were excluded from 
our study. Secondly, women with large symptomatic fibroids that cause dyspareunia may be 
more likely to abstain from intercourse as it may cause them too much discomfort, and these 
women were also excluded. Thus, it may be that we did not find a dose response relationship 
between fibroids and DD due to the exclusion of women with symptomatic fibroids who 
have either abstained from intercourse or have had a hysterectomy for their fibroids.
Interestingly younger women were more likely to experience DD as compared to the rest of 
the sample. Genital sexual pain that includes both superficial and deep pain has also been 
reported as more frequent among young women [12]. Because we lack information on 
partner characteristics and the frequency and vigorousness of coitus, we are unable to 
consider these factors in relation to age of the participant. However, it is possible that 
younger women may have confounding factors such as more frequent coitus, which could 
help explain this finding.
Our study has important strengths. A major strength is that it is a large sample with 
participants randomly selected from membership in a prepaid health plan. Another strength 
is that our study included large numbers of African American women who in general have a 
greater fibroid burden [13,14], but have been less studied. Importantly, our fibroid 
assessment relied on ultrasound screening, regardless of a prior clinical diagnosis. Fibroids 
often are not clinically diagnosed, so the ultrasound screening provided an unbiased 
determination of fibroid status. In addition, because of the extensive data collection effort 
and the large sample, we were better able than other studies to control for potential 
confounding factors such as number of deliveries.
There were also several weaknesses. As with the other studies, this is a cross-sectional data 
analysis, so we cannot determine causality. The association we observed between fibroids 
and DD could be due to shared causal pathways for the two conditions. Our questionnaire 
data assessing deep dyspareunia were based on self-reported responses to a series of 
symptom questions and did not involve clinical validation, nor did it take into consideration 
partner characteristics such as penis size which could contribute to DD severity. In addition, 
we only captured women who had such severe pain that it prevented them from normal 
activity. Pain scales that give a quantitative measure of pain (commonly used in a clinical 
setting) would also be informative. However, unlike some previously validated 
questionnaires, our DD questions do distinguish between pain felt deep inside and pain 
experienced at the vaginal introitus, which may have allowed us to better evaluate the 
association between fibroids and DD. Pain at the vaginal introitus during intercourse is 
likely to have different etiology such as atrophic vaginitis. While it appears that women with 
DD often have concomitant vaginal pain at the introitus, this is not always the case as is 
demonstrated in this study (35% of women with DD also reported pain at the vaginal 
introitus Table 1) In addition, our study like most cross-sectional studies is subject to 
selection bias. We excluded women who were not sexually active, and women who did not 
complete our DD assessment. We did investigate possible bias from excluding those not 
having sex by examining their level of fibroid burden. If they were less likely to have 
fibroids than those included in the analysis, this could have removed a subset of fibroid-free 
women with DD, thus creating the observed association by selection bias. However, we 
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found that those excluded due to not having sex had a higher prevalence of fibroids than 
those remaining in the analysis as would be expected if fibroids were associated with such 
severe DD that some women did not have intercourse. Thus, selection bias from this 
exclusion cannot explain our findings. Furthermore, excluding women who have had a 
previous hysterectomy due to large symptomatic fibroids may have biased our dose-response 
results towards the null as discussed above.
Like other published studies, we lacked data on some important confounders such as a 
history of sexual abuse, partner characteristics, and coital frequency. We used depression as 
a proxy for history of sexual abuse because depression can often be caused by a history of 
sexual abuse and trauma [15]. Partner characteristics and coital frequency may contribute to 
DD severity, and explain why younger women have a slightly greater risk of DD as 
compared to older women.
Lippmann et al. reported a stronger association with DD for women who had fundally-
located fibroids [9]. Though we collected fibroid location data, it included only women with 
fibroids ≥ 2.0 cm diameter (n=536). We also found that having at least one fundal fibroid 
among the evaluated fibroids was somewhat more strongly associated with having DD 
compared with having fibroids located only in the corpus or below. A possible explanation 
for why fundal fibroids might be linked with DD is that fundal fibroids might induce uterine 
retroversion of the uterus, which might affect pain. We had data on whether a uterus was 
retroverted, and when we examined that factor we found no association with DD 
aPORretroverted= 1.1(95% CI 0.64, 2.03). Another possible explanation for the importance of 
fundal fibroids is that they are anatomically furthest away from the perforating branches of 
the uterine artery that enters the uterus bilaterally near the cervico-uterine junction [16,17]. 
Furthermore, the architecture of the smooth muscle fibers change as one descends caudally 
from the fundus to the cervix. Criss-crossing longitudinal and oblique smooth muscle fibers 
are more abundant in the fundus and corpus, while circular smooth muscle fibers are more 
abundant in the cervix [18]. The criss-crossing smooth muscle fibers higher up in the uterine 
myometrium are much more efficient at constricting blood vessels than the musculature 
lower down near and in the cervix [18]. Thus fundal fibroids may be more prone to chronic 
devascularization, and ischemic infarction. While fibroids below the fundus may also 
increase inflammation and inflammatory cytokines involved in the pain pathways due to 
rapid growth and cell death cycles [19,20].
Another potential mechanism of action through which fibroids may cause pain during 
intercourse is by interfering with physiologic responses that facilitate normal conditions of 
intercourse. Fibroids might interfere with orgasm (which is characterized by contractions of 
the uterus, cervix, and vaginal musculature) or with tenting and cervical elevation during 
intercourse, which results in vaginal elongation and “ballooning “of the upper third of the 
vagina (a common physiologic occurrence during the arousal phase of the female sexual 
cycle) [21].
Delivery of a child has been shown to impact sexual functioning for women [22,23]. 
Although many factors are most likely leading to an overall decline in sexual functioning 
surrounding childbirth, one factor (perineal injury) may be specifically linked to the 
Moshesh et al. Page 9













development of DD. Some studies have observed that dyspareunia for many women improve 
by 6–12 months after childbirth regardless of the mode of delivery [23,24], other studies 
have shown that persistent dyspareunia after childbirth is linked to more severe tearing and 
or assisted vaginal deliveries [25,26,27]. While we did not distinguish between the modes of 
delivery in this study, we did observe that the number of deliveries was positively associated 
with the odds of having DD aPOR= 1.3 (95% CI 1.09, 1.47).
Many barriers exist when addressing issues of sexual dysfunction. It is often multi-factorial, 
patients are reluctant to discuss this issue, sparse treatment options are available, and it often 
requires a multi-disciplinary approach. However, its significant impact on women has 
become more apparent [28]. Our study that showed that women with fibroids are more likely 
to have dyspareunia than those without fibroids indicates that at the time of a fibroid 
diagnosis physicians might easily introduce questions about sexual function. Prospective 
data are needed to show whether fibroids can actually cause or exacerbate dyspareunia.
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Table 1
Characteristics of the study sample, NIEHS Uterine Fibroid Study, stratified by deep dyspareunia status.
Deep Dyspareunia Status
Population Characteristics No N= 668 n(%)* Yes N= 159 n(%)*
Fibroids Present
 Yes 410 (61) 113 (71)
 No 258 (39)   46 (29)
Fibroid Burden (Size of largest fibroid)
 0.5cm – 3.9cm 289 (43)   80 (50)
 4.0cm & over 121 (18)   33 (21)
Fibroid Burden (Uterine volume with fibroids present)
 Uterine Volume + fibroid < 150 cm3 225 (34)   64 (40)
 Uterine Volume + fibroid 150cm3 – 200cm3 133 (20)   35 (22)
 Uterine Volume + fibroid 300cm3 & Over   52 (8)   14 (9)
Age
 35–39 222 (33)   72 (45)
 40–44 247 (37)   58 (36)
 45–50 199 (30)   29 (18)
Ethnicity
 White 259 (39)   36 (23)
 Black 353 (53) 114 (72)
 Other   56 (8)     9 (6)
Education
 High school/or less   88 (13)   31 (20)
 Some college 194 (29)   65 (41)
 College 171 (26)   38 (24)
 Post graduate education 215 (32)   25 (16)
Number of Deliveries
 0 223 (33)   33 (21)
 1 133 (20)   35 (22)
 2 213 (32)   47 (30)
 3 or more   99 (15)   44 (28)
 missing     0     1
Depression
 No 566 (85) 116 (73)
 Yes 102 (15)   42 (27)
Pelvic Pathology†
 No 618 (93) 132 (83)
 Yes   50 (7)   27 (17)
Physical Activity‡
 Low 226 (34)   54 (34)
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Deep Dyspareunia Status
Population Characteristics No N= 668 n(%)* Yes N= 159 n(%)*
 Medium 225 (34)   49 (31)
 High 110 (16)   29 (18)
 Very High 106 (16)   25 (16)
 missing     1     2
Alcoholic Drinks Per Week
 0–0.5 234 (35)   75 (47)
 1.0–1.9 186 (28)   33 (21)
 2–6.9 128 (19)   29 (18)
 7 & Over 120 (18)   22 (14)
Body Mass Index
 Under 25 280 (42)   55 (35)
 25–29 192 (29)   41 (26)
 30–34   89 (13)   34 (22)
 35 & Over 107 (16)   28 (18)
 Missing     0     1
Abdominal Cramps
 None 213 (32)   18 (11)
 Less than 1 day per month 127 (19)   26 (16)
 1–4 day per month 288 (43)   88 (55)
 5 or more days per month   38 (6)   27 (17)
 Missing     2     0
Abdominal Bloating
 None 216 (32)   23 (14)
 Less than 1 day per month   69 (10)   15 (9)
 1–4 days per month 312 (47)   87 (55)
 5 or more days per month   70 (11)   34 (21)
 missing     1     0
Pain at Vaginal Opening with intercourse
 No 632 (95) 104 (65)
 Yes   35 (5)   55 (35)
 Missing     1     0
Dyspareunia at Age 30
 Never or less than 1 time per month 631 (95)   83 (52)
 Once a month or more   24 (4)   73 (46)
 Not sexually active at age 30   12 (2)     3 (2)




pelvic pathology included women who have a history of endometriosis, prolapse, or interstitial cystitis by symptom assessment.
‡
physical activity is categorized as follow (low=33rd percentile, medium=33-66th, high=67th-83rdpercentile, very high=above the 83rd percentile 
Breakdown for physical activity obtained from {Baird et al., Am J Epidemiol 2007:165:157–163}
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Table 2
Fibroid status by deep dyspareunia (DD) frequency, among women with DD. Ntotal = 159






Less than 1 day per month 67 28(42) 39(58)
1–4 days per month 65 12(18) 53(82)
4 or more days per month 27 6(22) 21(78)
*
percentage calculations based on row total
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Table 3
The association between fibroids and covariates with deep dyspareunia. Ntotal=823
Covariate * aPOR (95% CI)
Fibroids 1.7 (1.09,2.54)
Age 0.9 (0.87, 0.96)
Education 0.8 (0.67, 1.03)
Ethnicity
 African American 1.00 (reference)
 Caucasian 0.7 (0.44, 1.25)
 Other 0.6 (0.26, 1.22)
Number of Deliveries 1.3 (1.12, 1.54)
Depression 2.2 (1.45, 3.47)
Pelvic Pathology† 2.8 (1.64, 4.77)
Physical Activity‡ 1.1 (0.90, 1.27)
*
aPOR = adjusted prevalence odds ratios.
†
Pelvic pathology include women who have one of the following, endometriosis, prolapse, & or interstitial cystitis.
‡
Physical activity is categorized as followed (Low = lowest 33% percent of combined activity, Medium =33–66% range of physical activity, High= 
67th–83rd percentile of physical activity, Very high= above the 83rd percentile in physical activity. Breakdown for physical activity variable came 
from {Baird et al., Am J Epidemiol 2007;165:157–163}).
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Table 4
The association between fibroid burden and deep dyspareunia by uterine volume and by fibroid size.
Covariate Number of Women N (%) aPOR* (95% CI)
Fibroid Status
No Fibroids (reference) 304(37) 1.00
 Uterine Volume <150cm3 289(35) 1.8 (1.13, 2.80)
 Uterine Volume 150cm3–299cm3 168(20) 1.4 (0.84, 2.48)
 Uterine Volume 300cm3 & over 66(8) 1.8 (0.83, 3.73)
No Fibroids (reference) 304(37) 1.00
 Fibroid Size 0.5–3.99cm 369(45) 1.64 (1.1, 2.55)
 Fibroid Size 4.0cm & greater 154(19) 1.74 (1.0,3.05)
*
aPOR =adjusted prevalence odds ratios. (Adjusted for age, education, ethnicity, number of deliveries, depression, pelvic pathology, and physical 
activity.)
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